Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:  

9913.   Dugue C, Perraut R, Youinou P, Renaudineau Y. Effects of anti-endothelial cell antibodies in leprosy and malaria. Infect Immun. 2004 Jan;72(1):301-9.

9914.   Ebenezer GJ, Daniel E. Expression of protein gene product 9.5 in lepromatous eyes showing ciliary body nerve damage and a "dying back" phenomenon in the posterior ciliary nerves. Br J Ophthalmol. 2004 Feb;88(2):178-81.

9915.   Geluk A, van Meijgaarden KE, Franken KL, Wieles B, Arend SM, Faber WR, Naafs B, Ottenhoff TH. Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuberculosis. Scand J Immunol. 2004 Jan;59(1):66-70.

9916.   Imaz MS, Comini MA, Zerbini E, Sequeira MD, Latini O, Claus JD, Singh M. Evaluation of commercial enzyme-linked immunosorbent assay kits for detection of tuberculosis in Argentinean population. J Clin Microbiol. 2004 Feb;42(2):884-7

9917.   Ravindran R, Anam K, Bairagi BC, Saha B, Pramanik N, Guha SK, Goswami RP, Banerjee D, Ali N. Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy. Infect Immun. 2004 Feb;72(2):863-70.

9918.   Sinha S, Mahadevan A, Lokesh L, Ashraf V, Chandrasekhar Sagar BK, Taly AB, Shankar SK. Tangier disease--a diagnostic challenge in countries endemic for leprosy. J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):301-4.

Pathogenesis

9919.   de la Barrera S, Finiasz M, Fink S, Ilarregui J, Aleman M, Olivares L, Franco MC, Pizzariello G, del Carmen Sasiain M. NK cells modulate the cytotoxic activity generated by Mycobacterium leprae-hsp65 in leprosy patients: role of IL-18 and IL-13. Clin Exp Immunol. 2004 Jan;135(1):105-13.

9920.   Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, Rea TH, Brennan PJ, Belisle JT, Blauvelt A, Porcelli SA, Modlin RL. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J Clin Invest. 2004 Mar;113(5):701-8.

9921.   Matsuoka M, Zhang L, Budiawan T, Saeki K, Izumi S. Genotyping of Mycobacterium leprae on the basis of the polymorphism of TTC repeats for analysis of leprosy transmission. J Clin Microbiol. 2004 Feb;42(2):741-5.

9922.   Prevot G, Bourreau E, Pascalis H, Pradinaud R, Tanghe A, Huygen K, Launois P.  Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun. 2004 Feb;72(2):958-65.

Vaccines

9923.   Al-Attiyah R, Mustafa AS.  Computer-assisted prediction of HLA-DR binding and experimental analysis for human promiscuous Th1-cell peptides in the 24 kDa secreted lipoprotein (LppX) of Mycobacterium tuberculosis. Scand J Immunol. 2004 Jan;59(1):16-24.

Therapy

9924.   Crawford CL. Licensing thalidomide in Australia. Med J Aust. 2004 Feb 16;180(4):199-200; discussion 200.

9925.   Laffitte E, Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf. 2004 Jan;3(1):47-56. Review.

9926.   Staples J. Delineating disease: self-management of leprosy identities in South India. Med Anthropol. 2004 Jan-Mar;23(1):69-88.

9927.   Villahermosa LG, Fajardo TT Jr, Abalos RM, Cellona RV, Balagon MV, Dela Cruz EC, Tan EV, Walsh GP, Walsh DS. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. Am J Trop Med Hyg. 2004 Feb;70(2):197-200.